Clinical Trial Update: A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase II randomized, open-label study in Taiwan compares GASL (gemcitabine + nab-paclitaxel with S-1/LV) versus GAP (gemcitabine + oxaliplatin) as first-line …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)
• S-1/LV (S-1 with leucovorin)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Phase II, Open-label, Parallel 2-arm, Multi-center | Phase 2 | Status: ACTIVE_NOT_RECRUITING